Salarius Pharmaceuticals Inc (NAS:SLRX)

$ 1.67 0.0065 (0.39%) Market Cap: 2.41 Mil Enterprise Value: -558,000.00 PE Ratio: 0 PB Ratio: 0.82 GF Score: 29/100

Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
Sep 29, 2022
Q2 2022 Salarius Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2022

$44 (+9.95%)

Earnings
Q1 2022 Salarius Pharmaceuticals Inc Earnings Call Transcript
May 12, 2022

$44.4 (+38.75%)

Earnings
Q4 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
Mar 10, 2022

$100 (+33.40%)

Earnings
Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call Transcript
Jan 13, 2022
Q3 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
Nov 04, 2021

$167.02 (-1.14%)

Earnings
Salarius Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript
Sep 29, 2021
Q2 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2021

$160.54 (+0.97%)

Earnings
Salarius Pharmaceuticals Inc Virtual KOL & Investor Event Call Transcript
Jun 21, 2021
Q1 2021 Salarius Pharmaceuticals Inc Earnings Call Transcript
May 12, 2021

$230 (-4.17%)

Earnings
Q4 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
Mar 18, 2021

$300 (-5.06%)

Earnings
Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call Transcript
Feb 24, 2021
Q3 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
Nov 11, 2020

$152.76 (+2.55%)

Earnings
Q2 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2020

$214 (-4.46%)

Earnings
Q1 2020 Salarius Pharmaceuticals Inc Earnings Call Transcript
May 14, 2020

$167.96 (+0.87%)

Earnings
Salarius Pharmaceuticals Inc at SNN Network Transcript
Nov 20, 2019

Salarius Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) Transcript

Sep 29, 2021 / 02:50PM GMT

Release Date Price: $204 (-5.56%)

Transcript

Spencer Israel

Benzinga - Moderator

All right. Let's move on to our next -- -t seems like we're going back and forth this mroning. We're doing eyes, oncology, eyes, oncology, eyes, oncology. We're going back to oncology here with our next presentation, Salarius Pharmaceuticals. David Arthur is the CEO, and his team here. Guys, let's bring David on.

David? There he is. How are we doing? Good morning.

David Arthur

Salarius Pharmaceuticals, Inc. - CEO

Good morning, Spencer. Thanks for having us. And I'm glad that you're getting lots of oncology companies in here today.

Spencer Israel

Benzinga - Moderator

Yes. Well, yeah. The day is young yet. The day is young. We have the whole rest of the day, we got you, guys, we got tomorrow. But yeah, we're talking oncology, we're talking everything here at the Benzinga Small Cap Healthcare Conference. So that being said, I'm going to bring on your slides, and there they are. I'm going to step back stage and I'm going to give you the floor, sir, to tell us all about

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.